Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
B

Ratings ESG MSCI

Ratings BioArctic AB: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: BioArctic AB
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: BioArctic AB
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 26.64 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Rating Financials

BioArctic AB SectorSweden

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

BioArctic AB SectorSweden

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

BioArctic AB SectorSweden

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

BioArctic AB SectorSweden

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

BioArctic AB SectorSweden

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
297.65Cr
B
4.29TCr
AAA
3.21TCr -
2.93TCr
A
2.77TCr
AAA
1.96TCr -
B
- -
1.42TCr - -
1.29TCr
BBB
1.24TCr
AA
1.19TCr -
A
- -
Average 2.06TCr
A
Weighted average by Cap.
A
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW